Here are the DEF 14A proxy statements from Prothena Corporation plc (PRTA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow PRTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRTA filings page.
Prothena Corporation plc has called its 2026 annual general meeting for May 14, 2026 in Dublin. Shareholders will vote on re‑electing directors Shane M. Cooke and Dennis J. Selkoe, ratifying KPMG LLP as auditor, and approving 2025 executive pay in an advisory “say‑on‑pay” vote.
Only holders of the company’s 53,832,982 ordinary shares as of March 2, 2026 may vote, one vote per share, with a simple majority of votes cast required for each proposal. The proxy details extensive governance practices, director independence, and committee structures.
The filing also reviews 2025 performance: termination of birtamimab after a failed Phase 3 trial and a workforce reduction of about 63%, alongside progress in partnered late‑stage programs with Roche, Novo Nordisk, and Bristol Myers Squibb. Prothena reports cash used in operating and investing activities of $163.7M, better than guidance, and year‑end liquidity of $308.4M, above a $298.0M target.